Advaxis is an American company devoted to the discovery, development and commercialization of immunotherapies based on a technology platform which uses engineered Listeria monocytogenes . The company is headquartered in Princeton, New Jersey and was incorporated in Delaware in 2006.The Lm-based platform on which the company's products are based involves the use of attenuated Lm which secrete antigen/adjuvant fusion proteins and stimulate a patient's immune system to mount an immune response to the secreted antigen; if the antigen is specifically found on cancerous cells, then the result aims to be an effective immune response targeting and eliminating the cancer. Treatments developed using this paradigm are referred to as Lm-LLO immunotherapies.Today, the Company has over fifteen distinct constructs in various stages of development, directly developed by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others.The Company also has a veterinary medicine program that is evaluating an Lm-LLO based immunotherapy in a Phase 1 study in canine osteosarcoma. Source: www.advaxis.com Wikipedia.
University of Pennsylvania and Advaxis | Date: 2016-12-22
The present invention provides KLK3 peptides, FOLH1 peptides, recombinant polypeptides comprising same, recombinant nucleotide molecules encoding same, recombinant Listeria strains comprising same, and immunogenic and therapeutic methods utilizing same.
Advaxis | Date: 2017-03-01
The present invention provides methods of treating, protecting against and inducing an immune response against a tumor or cancer, comprising the step of administering to a subject a recombinant Listeria strain. In one embodiment the present invention relates to a recombinant Listeria strain, said recombinant Listeria strain comprising a recombinant nucleic add, said nucleic add comprising a first open reading frame encoding a recombinant polypeptide comprising a first N-terminal fragment of an LLO protein fused to a heterologous antigen or fragment thereof, and wherein said recombinant nucleic add further comprises a second open reading frame encoding a mutant PrfA protein.
Advaxis and University of Pennsylvania | Date: 2017-01-04
This invention provides compositions and methods for treating and vaccinating against a HER2eu antigen-expressing tumor and inducing an immune response against the same in a subject.
Advaxis and The United States As Represented By The Secretary | Date: 2017-05-24
The present invention is directed to compositions comprising an immune checkpoint inhibitor or a T cell stimulator or a combination thereof, and a live attenuated recombinant Listeria strain comprising a fusion polypeptide comprising a truncated Listeriolysin O protein, a truncated ActA protein, or a PEST amino acid sequence fused to a tumor-associated antigen. The invention is further directed to methods of treating, protecting against, and inducing an immune response against a tumor or a cancer, comprising the step of administering the same.
Advaxis and U.S. National Institutes of Health | Date: 2017-01-11
The present invention is directed to methods for increasing T-cell effector cell to regulatory T cell ratio. The invention is further directed to methods of treating, protecting against, and inducing an immune response against a tumor, comprising the step of administering to a subject a recombinant Listeria strain, comprising a fusion peptide that comprises an LLO fragment and tumor-associated antigen.
Advaxis and City Of Hope | Date: 2017-05-24
Disclosed herein are recombinant nucleic acids encoding tumor antigens fused to immunogenic polypeptides and recombinant Listeria strains comprising the same, methods of preparing same, and methods of inducing an immune response, and treating, inhibiting, or suppressing cancer or tumors comprising administering same.
Advaxis | Date: 2016-06-24
This invention provides a system of providing and a process of creating personalized immunotherapeutic compositions for a subject having a disease or condition, including therapeutic vaccine delivery vectors comprising gene expression constructs expressing peptides associated with one or more neo-epitopes or peptides containing mutations that are specific to an subjects cancer or unhealthy tissue. The invention further provides a scalable fully enclosed single use cell growth system, wherein the entire process of manufacturing of personalized immunotherapeutic compositions, up to and including dispensing said composition into containers for patient delivery is carried out within a single enclosed fluid flow path.
Advaxis and Sharp Corporation | Date: 2017-07-26
The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Listeria based strain that expresses prostate-tissue specific antigen (PSA), and the use of the combination therapies for the treatment of prostate cancer.
Advaxis, University of Pennsylvania and Foundation University | Date: 2016-07-27
This invention provides methods and compositions for using Listeria monocytogenes as an adjuvant for enhancing immune responses in a subject.
Advaxis | Date: 2016-02-03
The present disclosure provides methods of treating, protecting against, enhancing and inducing an immune response against a tumor or cancer, comprising the step of administering to a subject a recombinant Listeria. In other embodiments, the Listeria stimulates the STING pathway.